Biogen (BIIB) Tops Q4 EPS by 57c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.05, $0.57 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.44 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.87.
- Mid-single digit revenue decline vs 2022
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Grand Canyon Education (LOPE) Tops Q3 EPS by 1c
- Solid Biosciences (SLDB) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
